OPEN

Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children

Chee Fu Yung^{1,2,3}, Xiangmei Ma⁴, Yin Bun Cheung^{4,5}, Bee Khiam Oh¹, Sally Soh⁶ & Koh Cheng Thoon^{1,3,7}

Kawasaki disease (KD) is a systemic vasculitis mainly affecting young children and the leading cause of acquired heart disease in developed countries. We performed a self-controlled case series analysis to investigate the association between PCV13 and KD. All hospitalized KD cases <2 y old from our hospital in Singapore from 2010 to 2014 were included. Complete KD cases were classified based on the definitions of the American Heart Association. During the study period, 288 KD cases were identified. A total of 21 KD cases (12 were classified as Complete KD) had date of onset within the risk interval of day 1 to day 28 post PCV13. The age-adjusted Relative Incidence (RI) for KD following PCV13 dose 1, dose 2 and dose 3 were 1.40 (95% CI, 0.72 to 2.71), 1.23 (95% CI, 0.62 to 2.44) and 0.34 (95% CI, 0.08 to 1.40) respectively. There were seven Complete KD cases with onset during the risk interval after dose 1 of PCV13 (age-adjusted RI 2.59, 95% confidence interval (CI), 1.16 to 5.81). We did not detect a significant increased risk for overall KD among PCV13 recipients.

Kawasaki disease (KD) is a systemic vasculitis characterised by specific clinical features mainly affecting infants and young children. Diagnosis is based primarily on clinical criteria as there is no specific confirmatory laboratory test available¹. It can trigger changes to the coronary arteries (approximately 25% of untreated KD) in some children resulting in death or long term morbidity. However, the risk of coronary artery aneurysm (CAA) can be reduced with prompt immunoglobulin treatment. The aetiology of KD remains unknown although it is now the leading cause of acquired heart disease amongst children in North America, Europe and Japan¹. KD has been reported worldwide but the epidemiology varies significantly between countries or regions. Reported incidences from North-Asian countries such as Japan and Korea are 10–20 times higher than incidences from USA and Europe².

A 7-valent pneumococcal conjugate vaccine (PCV7) (Prevenar; Wyeth) and subsequently a 13-valent pneumococcal conjugate vaccine (PCV13) (Prevenar 13; Pfizer) was licensed by the Food and Drug Administration (FDA) in 2000 and 2010 respectively. Implementation of public health Pneumococcal conjugate vaccine (PCV) immunization programmes, particularly in developed countries have led to substantial reduction in diseases such as pneumonia, bacteremia and meningitis caused by *S. pneumonia* infection^{3,4}. Currently, PCV13 is recommended as a 4 dose schedule, administered at 2, 4, 6 months with a booster at 12–15 months by the Advisory Committee on Immunization Practices (ACIP)⁵. In some countries such as the United Kingdom, a 3 dose schedule at 2, 4 and 12–15 months is recommended. In Singapore, PCV7 was licensed in 2002 and PCV13 since 2010. Pneumococcal conjugate vaccine was formally recommended in the national childhood immunisation schedule

¹Infectious Disease Service, KK Women's and Children's Hospital, 100 Bukit Timah Road, 229899, Singapore, Singapore. ²Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, 308232, Singapore, Singapore. ³Duke-NUS Medical School, 8 College Road, 169857, Singapore, Singapore. ⁴Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore. ⁵Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland. ⁶Vigilance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore, Singapore. ⁷Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, National University Health System Building (NUH), 119228, Singapore, Singapore. Correspondence and requests for materials should be addressed to C.F.Y. (email: Yung.Chee.Fu@singhealth.com.sg)

Complete KD	Incomplete KD
Fever $\geq$ 5 days	Fever $\geq$ 4 days
AND	AND
At least 4 of the following 5 clinical features:	At least 2 or 3 of the 5 clinical features:
- Oromucosal: Erythema; Crusting of Lips; Strawberry Tongue	- Oromucosal: Erythema; Crusting of Lips; Strawberry Tongue
- Conjunctival injection	- Conjunctival injection
- Polymorphous skin rash	- Polymorphous skin rash
- Extremities: Induration of hands and feet; Peeling of skin	- Extremities: Induration of hands and feet; Peeling of skin
- Cervical lymphadenopathy ($\geq$ 1.5 cm diameter)	- Cervical lymphadenopathy ($\geq$ 1.5 cm diameter)

Table 1. Case definitions for Complete KD and Incomplete KD.

by the Ministry of Health in 2010 as a 3 dose schedule at 3 months followed by a second dose at 5 months and booster at 12 months. However, the licensed 4 dose schedule option similar to the ACIP is also used especially by private healthcare providers.

To date, only a handful of published studies have investigated the link between PCV and KD. A phase IV database analysis by Center *et al.* reported an increased risk of KD hospitalizations amongst recipients of PCV7 compared to historical controls (unadjusted RR 2.02 (95% CI, 1.16 to 3.63)⁶. However, after controlling for possible confounders including sex, race, age at first dose, etc., the RR of KD hospitalization was no longer statistically significant (RR 1.67; 95% CI, 0.93 to 3.00)⁶. Tseng *et al.* compared risk of KD between recipients of PCV13 versus PCV7 but did not find a statistically significant increase in risk although the point estimate RR was 1.94⁷. An evaluation of 29 KD cases for PCV7 reported to the Vaccine Adverse Event Reporting System (VAERS) in USA up to 2007 did not find any increased risk⁸. In another study, recipients of PCV13 were found to have an elevated but statistically non-significant risk of KD in the 28 days following immunization compared to historical controls who were recipients of PCV7 (RR 1.94, 95%CI, 0.79 to 4.86)⁷. More recently, a report from the Sentinel initiative, Center for Biologics Evaluation and Research (CBER) using 87 confirmed KD cases in a self-controlled risk interval analysis identified no elevated risk of KD amongst PCV13 recipients (relative risk (RR) 1.07, 95%CI, 0.70 to 1.63)⁹. In the same report, a cohort analysis method composed of 80 potential KD cases (based on claims) in the 1 to 28 days risk window also found no elevated risk of KD (RR 0.84, 95%CI, 0.65 to 1.08).

In this paper, we aim to investigate the association between PCV13 and KD using the self-controlled case series (SCCS) study design¹⁰. Our apriori null hypothesis stated that the risk of KD within the 28 day risk interval following receipt of any PCV13 dose was the same as control periods outside the risk window.

Methods

Study setting. KK Women's and Children's Hospital (KKH) is the single largest public healthcare specialist women's and children's hospital in Singapore. The hospital has approximately 800 beds and is the site of an ongoing active surveillance vaccine safety programme set up in 2009 in collaboration with the Health Sciences Authority (Singapore's regulatory authority on medical products). Details of this active surveillance system were previously described¹¹. Briefly, all paediatric admissions to the hospital are prospectively screened for a specific range of diseases and syndromes including KD. Detailed clinical and laboratory information are collected together with immunization history for the purpose of monitoring safety in childhood immunizations.

Data sources and definitions. We extracted all hospitalized cases of KD in our surveillance database from 1st January 2010 to 31st December 2014. To ensure complete extraction of all KD cases admitted to KKH, we also screened the hospital discharge database for KD cases using International Classification of Diseases (ICD), Ninth Revision and Tenth Revision KD codes 446.1 and M30.3 respectively, in any diagnostic field. The immunization history of each case was obtained from the child's health information booklet. In addition, the patient's identifiers and unique national identity number was linked with the National Immunisation Registry (NIR) which records childhood immunizations administered by all private and public healthcare providers in Singapore. Ethics approval was obtained from the SingHealth Centralized Institutional Review Board, Singapore.

For the purpose of this study, only cases with age of onset <2 years and children who were citizens or permanent residents of Singapore were included in the study. Cases who had ever received PCV7 were excluded. We classified KD cases based on the definitions of the American Heart Association (AHA) KD Scientific Statement as shown in Table 1. Complete KD was defined as five or more days of fever AND evidence of at least four of the five main clinical manifestations. This was similar to the level 1a diagnostic certainty criteria developed by the Brighton Collaboration except that their criteria require only four days of fever¹². Incomplete KD were defined as cases with prolonged unexplained fever AND <4 of the five main clinical manifestations (Table 1).

Statistical analysis. We used the SCCS method, which used case patients only to compare the chance of an outcome occurring in fixed intervals of time after immunization relative to unexposed times^{10,13}. The observation period was from 1st January 2010 to 31st December 2014. Risk intervals after each PCV13 dose were defined as day 1 to day 28 following receipt of the vaccine with day 0 being the day of immunization. All other times during the observation period were defined as 'unexposed' periods (control interval). We used the documented date of fever onset as the date of onset of KD. KD cases with fever onset on day of PCV13 immunization (day 0) were excluded from analysis.

Figure 1. Consort flow diagram of criteria for case inclusion and exclusion.

Relative incidence (RI) of KD during the risk interval compared to the control interval was estimated using conditional Poisson regression¹⁰. Separate stratified analysis for Complete KD and Incomplete KD were also performed. In view of the known varying incidence of KD by age, for our primary analysis we adjusted for age in the model using four predetermined age categories: 0 m to <6 m, 6 m to <12 m, 12 m to <18 m, 18 m to <24 m. The primary analysis included all eligible KD cases regardless of PCV vaccination status as information from unvaccinated cases facilitated estimation and controlling of age effect. We also performed additional sensitivity analysis using monthly age interval as a cubic spline function with one knot at 12 months old as well as using vaccinated cases only¹⁴. Although the risk of KD is known to be higher in males, the SCCS negated the need to control for such fixed confounders. The two-sample t-test was used for comparison of continuous variables between groups, and the Fisher's exact test was used for categorical variables. Statistical analysis were two-tailed and $P < 0.05$ was considered significant. All statistical analysis were performed using Stata (Version 13.1).

Ethical approval was granted from the SingHealth Centralised Institutional Review Board (Reference Number: 2012/340/E). All research was performed in accordance with relevant guidelines/regulations. Waiver of informed consent was granted by the ethics committee. The study did not involve any experiments on humans and/or the use of human tissue samples.

Results

Kawasaki disease cases. From 1st January 2010 to 31st December 2014, 366 KD cases <2 years old were admitted to KK Hospital. From these, we excluded 74 cases with a positive history of PCV7 immunization, three cases with onset of fever/KD on the day of immunisation and one case with a likely PCV13 immunisation date record error (only three days between dose 1 and dose 2) (Fig. 1). Among the final 288 KD cases used in the analysis, 172 (60%) were Complete KD cases. There were slightly more male cases (57%) and 192 (66%) had a positive history of PCV13 immunization. As shown in Table 2, there were no major differences between KD cases in terms of PCV13 status for various demographic and clinical characteristics: age at presentation, gender, length of hospital admission and days of fever prior to admission. Only the ethnic distribution between the two groups were found to be statistically significantly different ($p = 0.018$).

Risk of kawasaki disease following PCV13 immunization. A total of 21 KD cases had date of onset within the risk interval of day 1 to day 28 post PCV13 immunization (Table 3). Amongst the 21 KD cases 12 were classified as Complete KD and 9 were Incomplete KD. There were 10, 9, 2 and 0 KD cases with date of onset within the risk interval after PCV13 dose 1, dose 2, dose 3 and dose 4 respectively (Fig. 2). The age-adjusted RI for KD following PCV13 dose 1, dose 2 and dose 3 were 1.40 (95%CI, 0.72 to 2.71), 1.23 (95% CI, 0.62 to 2.44) and 0.34 (95% CI, 0.08 to 1.40) respectively (Table 4). All KD cases in our cohort with onset within the risk interval received Intravenous Immunoglobulin (IVIG) and aspirin treatment. None had evidence of coronary artery dilatation or aneurysm in their final echocardiogram.

Upon stratified analysis, there were seven Complete KD cases during the risk interval after dose 1 of PCV13 (age-adjusted RI 2.59, 95% confidence interval (CI), 1.16 to 5.81) (Table 4). The age-adjusted RI for Complete KD following dose 2 of PCV13 was not statistically significant (age-adjusted RI 1.31, 95% CI, 0.52 to 3.28). No Complete KD cases occurred during the risk interval after dose 3 or dose 4 of PCV13. In the Incomplete KD group, there were three Incomplete KD cases during the risk interval after dose 1 of PCV13 (age-adjusted RI 0.65, 95%CI, 0.20 to 2.12). The RI of Incomplete KD during the risk interval for subsequent PCV13 doses was also not statistically significantly higher than the control interval (Table 4).

Sensitivity analysis. We detected similar RI for KD following PCV13 immunization in the sensitivity analysis. Details reported in Supplementary Tables 1 and 2. In summary, the age-adjusted (monthly interval) RI for Complete KD within the risk interval following dose 1 of PCV13 was 2.31 (95%CI, 1.02 to 5.23). When only

Variables	Unvaccinated (n = 96)	KD	P value*	Unvaccinated (n = 61)	Complete KD	P value*	Unvaccinated (n = 35)	Incomplete KD	P value*
		Vaccinated (n = 192)			Vaccinated (n = 111)			Vaccinated (n = 81)	
Age at Admission (month)									
Mean	12.24	11.32	0.228	13.12	12.65	0.597	10.69	9.50	0.352
Median	12.29	10.53		12.65	11.93		9.99	7.82	
Range	1.35–23.52	1.58–23.89		2.86–23.52	2.53–23.52		1.35–23.13	1.58–23.89	
Sex									
Male	55 (57.29%)	109 (56.77%)	1.000	34 (55.74%)	63 (56.76%)	1.000	21 (60.00%)	46 (56.79%)	0.839
Female	41 (42.71%)	83 (43.23%)		27 (44.26%)	48 (43.24%)		14 (40.00%)	35 (43.21%)	
Ethnicity									
Chinese	63 (65.63%)	152 (79.17%)	0.018	41 (67.21%)	86 (77.48%)	0.247	22 (62.86%)	66 (81.48%)	0.065
Malay	23 (23.96%)	23 (11.98%)		14 (22.95%)	14 (12.61%)		9 (25.71%)	9 (11.11%)	
Indian	6 (6.25%)	5 (2.60%)		3 (4.92%)	3 (2.70%)		3 (8.57%)	2 (2.47%)	
Others	4 (4.17%)	12 (6.25%)		3 (4.92%)	8 (7.21%)		1 (2.86%)	4 (4.94%)	
Total Length of Stay									
Mean	4.99	5.15	0.572	4.79	4.73	0.854	5.34	5.72	0.476
Median	5	4		4	4		5	5	
Range	2–12	2–24		2–11	2–14		2–12	2–24	
Days of Fever before Admission									
Mean	3.56	4.09	0.069	3.70	3.92	0.510	3.31	4.33	0.048
Median	3	4		4	4		3	4	
Range	0–14	0–21		0–14	0–15		0–6	0–21	

Table 2. Characteristics of participants and KD disease episodes, by PCV13 vaccination status and stratification for Complete KD or Incomplete KD. *Fisher's exact test is used for categorical variables; two-sample t-test for quantitative variables.

Actual dose number of PCV received	KD	Complete KD	Incomplete KD
Children received 1 st dose	188	109	79
Episodes within 1 st dose's risk period	10	7	3
Children received 2 nd dose	165	95	70
Episodes within 2 nd dose's risk period	9	5	4
Children received 3 rd dose	126	82	44
Episodes within 3 rd dose's risk period	2	0	2
Children received 4 th dose	19	11	8
Episodes within 4 th dose's risk period	0	0	0

Table 3. Number of Kawasaki disease episodes during risk periods by PCV13 dose.

vaccinated cases (N = 111) were used for analysis, the RI for Complete KD following dose 1 of PCV13 was 2.16 (95%CI, 0.95 to 4.93). The risk of KD for subsequent doses of PCV13 were not statistically significantly elevated.

Discussion

We did not detect a statistically significant increased risk for KD among PCV13 recipients, for any of the four doses. However, an approximate two fold increased risk of Complete KD within the 28 day risk interval following receipt of the first dose of PCV13 compared to control periods outside the risk window was noted. This could be a chance finding as no adjustment was made for multiple comparisons. Of the 8 associations tested, in all but one test we found no evidence for an association between PCV13 and KD risk. Subsequent doses of PCV13 did not result in an increased risk of Complete KD. Reassuringly, all KD cases with onset within the risk interval were treated (Intravenous Immunoglobulin (IVIG) and aspirin) and none had evidence of coronary artery sequelae in their final echocardiogram.

An important strength of our analysis was the use of the SCCS study design. It allowed us to mitigate fixed confounders relevant to KD such as gender and genetics. Genetic mutations have been reported to contribute to the well documented regional and ethnic variations in incidence of KD globally^{15,16}. Observational study design's inability to control for differences in genetic susceptibility to KD as well as other unknown fixed confounders could generate biased findings. To date, there is only one other self-controlled analysis on the subject as stated earlier. The investigation report by the Sentinel initiative, CBER found no statistically significant increased risk for KD among PCV13 recipients⁹. However, apart from the smaller sample size of 87 confirmed KD cases compared to our larger sample size of 288 KD cases, there were also other key differences in methodology. Firstly, in the US study, cases were identified electronically via ICD codes rather than prospectively via active case surveillance.

Figure 2. Temporal distribution of KD cases within 28 days of dose 1 PCV13 vaccination.

	KD		Complete KD		Incomplete KD	
	Age-adjusted RI (95% CI)	P value	Age-adjusted RI (95% CI)	P value	Age-adjusted RI (95% CI)	P value
Exposed for Dose 1	1.40 (0.72, 2.71)	0.316	2.59 (1.16, 5.81)	0.020	0.65 (0.20, 2.12)	0.479
Exposed for Dose 2	1.23 (0.62, 2.44)	0.545	1.31 (0.52, 3.28)	0.566	1.15 (0.41, 3.17)	0.792
Exposed for Dose 3	0.34 (0.08, 1.40)	0.136	NA	NA	1.22 (0.29, 5.14)	0.786
Exposed for Dose 4	NA	NA	NA	NA	NA	NA
Age(6m- < 12 m)	1.79 (1.29, 2.50)	0.001	3.06 (1.86, 5.04)	0.000	1.06 (0.66, 1.68)	0.812
Age(12m- < 18 m)	1.67 (1.17, 2.39)	0.005	3.29 (1.96, 5.53)	0.000	0.75 (0.43, 1.30)	0.298
Age(18m-24m)	1.23 (0.83, 1.82)	0.295	2.39 (1.37, 4.16)	0.002	0.57 (0.31, 1.06)	0.077

Table 4. Age-adjusted Relative Incidence (RI) of KD following PCV13 by dose. NA: Not applicable.

Secondly, there was a protocol violation where KD cases with delayed hospitalization occurring 71 to 84 days after PCV vaccination would not have been captured. Thirdly, their adjustment for age was based on another database of KD cases ('Kids' Inpatient Database, Healthcare Cost and Utilization Project') from 2009 while KD cases included for their analysis were recruited from 2010 to 2015. The smaller sample size and variations in methodology may account for the differing results. A cohort design by the same group also found no statistically significant association but in order to increase sample size, cases without chart verification (32% of cohort) were included. Therefore, considering the difficult challenge in diagnosing KD, the possible inclusion of non-KD cases could have been biased the results of the cohort analysis. Apart from the above report, there were no published studies directly comparing the risk of KD following PCV13 using controls who had not received PCV.

In our stratified analysis, the point estimate RI of KD following PCV13 was 2.59 for Complete KD which contrasted with the RI for Incomplete KD at 0.65. However, the Incomplete KD's RI had a 95%CI which overlapped 1 (95%CI, 0.20 to 2.12). It is likely that this difference in risk between PCV13 and Complete KD versus Incomplete KD may be attributable to challenges in diagnosing KD due to the absence of any confirmatory laboratory test. Diagnosing Complete KD requires a more stringent criteria and hence, it was probable that the specificity would be higher in contrast to Incomplete KD. Misclassification or wrongly diagnosed KD cases in the Incomplete KD group could inadvertently negate any existing causative link between PCV13 and KD. Interestingly, vaccinated Incomplete KD cases had a duration of fever before they presented to hospital which was one day longer than unvaccinated cases ($p = 0.048$). This may suggest that these cases may have had less severe clinical manifestations which could make it harder to accurately diagnose KD. In contrast, there were no differences in duration of fever before hospitalization by vaccination status for the Complete KD group. Misclassification was also less likely in the Complete KD group since our case definition for Complete KD was actually stricter than the level 1a Brighton collaboration criteria. We required that patients had at least five days of fever similar to the AHA guidelines, instead of only four days. Our finding highlights the importance for future studies to differentiate Complete and Incomplete KD, preferably using standardised case definitions such as the AHA guidelines or Brighton Collaboration¹². Earlier studies such as the study by Center *et al.* did not specify the criteria used to define KD except that it was 'pre-specified' in collaboration with the FDA⁶. However, mean duration of fever was reported to be six days which may suggest that Incomplete KD cases were included. Based on our study findings, this inclusion may have biased the analysis towards the null hypothesis for the association between PCV7 and KD.

A limitation of our study, similar to any study involving vaccination records, is the possible misclassification of PCV13 vaccination status. To mitigate this, we excluded subjects who may not be residing permanently in Singapore as they may have received PCV13 from abroad. We also collated vaccination histories from multiple sources: patient's health booklet, National Immunization Registry and medical chart review. In addition, our findings were robust to sensitivity analysis using vaccinated cases only. Therefore, we believe it is unlikely that misclassification of PCV13 vaccination status could have biased our findings. We did not adjust for possible effects from concurrent vaccines given around the same time as PCV13. However, reviewing the immunization histories of the 7 Complete KD cases with onset with the first PCV13 dose risk window only identified 3 cases having received concurrent 5-in-1 vaccine (diphtheria, tetanus, pertussis, polio and *Haemophilus influenza* type b) within the prior 28 days. Two cases were vaccinated 27 days and one 14 days before onset of KD. Although there has been reports of temporal association of KD with childhood vaccinations, no causal association has been established with any childhood vaccines^{12,17}. The variability of KD incidence by age could also confound the analysis of the relationship between PCV13 and KD. We adjusted for age in our primary model to mitigate this. Additional sensitivity analysis categorising age by smaller monthly units produced similar results. Finally, time varying factors such as seasonality and environmental factors which have been reported to be possible risk factors for KD, were also potential confounders which could limit our findings. However, the seasonality of KD has mainly been reported in temperate regions rather than tropical countries like Singapore, and furthermore, current evidence for a possible role of environmental factors remain inconclusive².

Conclusions

In conclusion, using a self-controlled case series design, we did not detect a statistically significant association between PCV13 and overall KD. Although post hoc subgroup analyses of Complete KD (uncorrected for multiple comparisons) suggested a marginal association (for first PCV13 dose in children < 2 years old), this may well represent a type I error. There was no evidence of any coronary artery sequelae following appropriate treatment for Complete KD following receipt of PCV13. Hence, whilst our data overall suggests that the vaccine does not pose a risk, ongoing surveillance for any adverse events (including KD) related to vaccination is warranted. Early diagnosis and appropriate treatment of KD remains important.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

1. McCrindle, B. W. *et al.* Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation*. **135**, e927–e999 (2017).
2. Uehara, R. & Belay, E. D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. *J Epidemiol.* **22**, 79–85 (2012).
3. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. *Morb Mortal Wkly Rep.* **57**, 144–148 (2008).
4. Moore, M. R. *et al.* Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. *Lancet Infect Dis.* **15**, 301–309 (2015).
5. Nuorti, J. P. & Whitney, C. G., Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* **59**, 1–18 (2010).
6. Center, K. J., Hansen, J. R., Lewis, E., Fireman, B. H. & Hilton, B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between kawasaki disease and seven-valent pneumococcal conjugate vaccine. *Pediatr Infect Dis J.* **28**, 438–440 (2009).
7. Tseng, H. F. *et al.* Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. *Vaccine.* **31**, 2578–2583 (2013).
8. Hua, W. *et al.* Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990–2007. *Pediatr Infect Dis J.* **28**, 943–947 (2009).
9. Baker, M. A. *et al.* 13-valent Pneumococcal conjugate vaccination and Kawasaki disease during the first 2-years of life. *Sentinel CBER Final Report.*, https://www.sentinelinitiative.org/sites/default/files/vaccines-blood-biologics/assessments/Sentinel_CBER_Final_Report_Kawasaki_Disease_13-Valent_Pneumococcal_Conjugate_Vaccination.pdf (2018).
10. Whitaker, H. J., Farrington, C. P., Spiessens, B. & Musonda, P. Tutorial in biostatistics: the self-controlled case series method. *Stat Med.* **25**, 1768–1797 (2006).
11. Thoon, K. C. *et al.* Active surveillance of adverse events following childhood immunization in Singapore. *Vaccine.* **32**, 5000–5005 (2014).
12. Phuong, L. K. *et al.* Kawasaki disease and immunisation: standardised case definition & guidelines for data collection, analysis. *Vaccine.* **34**, 6582–6596 (2016).
13. Yung, C. F., Chan, S. P., Soh, S., Tan, A. & Thoon, K. C. Intussusception and monovalent rotavirus vaccination in Singapore: self-controlled case Series and risk-benefit study. *J Pediatr.* **167**, 163–168 (2015).
14. Cheung, Y. B. *Statistical analysis of human growth and development* (CRC Press, 2013).
15. Kuo, H. C. *et al.* Genome-wide association study identifies novel susceptibility genes associated with coronary artery aneurysm formation in Kawasaki disease. *PLoS One.* **11**, 0154943, <https://doi.org/10.1371/journal.pone.0154943> (2016).
16. Yoon, K. L. Update of genetic susceptibility in patients with Kawasaki disease. *Korean J Pediatr.* **58**, 84–88 (2015).
17. Phuong, L. K. *et al.* Brighton Collaboration Kawasaki Disease (KD) Working Group. Kawasaki disease and immunisation: a systematic review. *Vaccine.* **35**, 1770–1779 (2017).

Acknowledgements

We thank A/Prof. Chong C.Y., Dr. Natalie Tan W.H. and Ms. Peck Li Fung for their support of the childhood vaccine safety surveillance programme. This work was part supported by the Ministry of Health, administered by the Health Sciences Authority, Singapore. The funders of the study had no role in study design, data collection, data analysis or decision to publish. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding source.

Author Contributions

C.F.Y. conceived and designed the study, involved in the collection, analysis and interpretation of the data and drafted the manuscript. Y.B.C. and X.M. were involved in the data analysis and provided inputs in drafting the manuscript. B.K.O., K.C.T. and S.S. were involved in data collection and provided inputs in drafting the manuscript. All authors approved the paper as submitted and agreed to be accountable for all aspects of the work.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-51137-5>.

Competing Interests: The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019